Back to Faculty
Faculty

Rebecca Porter

MD, PhD
Assistant Professor
Dana-Farber Cancer Institute

Dr. Rebecca Porter, MD, PhD is a Medical Oncologist in the Division of Gynecologic Oncology at Dana Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School. She also serves as the Director of Immunotherapy Research for the Division of Gynecologic Oncology, and her clinical and research efforts are centered on developing and translating novel immunotherapy strategies, including adoptive cell therapies, to patients with gynecologic cancers as well as performing biomarker studies to identify mediators of response and resistance to therapy. Dr. Porter maintains an active clinical practice seeing patients with ovarian, endometrial, cervical, vaginal and vulvar cancers.

2026 Sessions

Treatment of Platinum-Sensitive and Resistant Recurrent Ovarian Cancer: Optimizing Outcomes with Currently Available Therapies – The Regulatory Standard Is the Treatment Standard vs Rethinking Recurrent Ovarian Cancer – ADCs, New Taxane Combinations,

  • Moderator
    • Kathleen Moore
  • Presenter
    • Linda Duska
    • Rebecca Porter
Gynecological Cancers

Rethinking Recurrent Ovarian Cancer – ADCs, New Taxane Combinations, Bispecifics – What Will the Future of Treatment Selection Look Like?

  • Presenter
    • Rebecca Porter
Gynecological Cancers

Mirvetuximab and Emerging ADCs Should Define Treatment Selection by Biomarker

  • Debate Speaker
    • Rebecca Porter
Gynecological Cancers

Recurrent Ovarian Cancer in the ADC Era: Mirvetuximab and Emerging ADCs Should Define Treatment Selection by Biomarker vs Platinum Sensitivity Still Rules: Sequencing, Not Target Expression, Should Drive Decisions

  • Moderator
    • Kathleen Moore
  • Presenter
    • Marina Frimer
    • Rebecca Porter
Gynecological Cancers
Back to top